\n<\/p>\n
\n \n \n Add topic to email alerts \n <\/span> \n <\/p>\n\n\n \n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nAficamten became the first cardiac myosin inhibitor to show benefit in patients with nonobstructive hypertrophic cardiomyopathy.<\/li>\nIn the ACACIA-HCM trial, aficamten improved HF symptoms and peak VO2<\/sub>.<\/li>\n<\/ul>\nAficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial. <\/p>\nThe results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population. <\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\nFor the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\nEach patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\nAficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
\n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nAficamten became the first cardiac myosin inhibitor to show benefit in patients with nonobstructive hypertrophic cardiomyopathy.<\/li>\nIn the ACACIA-HCM trial, aficamten improved HF symptoms and peak VO2<\/sub>.<\/li>\n<\/ul>\nAficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial. <\/p>\nThe results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population. <\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\nFor the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\nEach patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\nAficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
“ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nAficamten became the first cardiac myosin inhibitor to show benefit in patients with nonobstructive hypertrophic cardiomyopathy.<\/li>\nIn the ACACIA-HCM trial, aficamten improved HF symptoms and peak VO2<\/sub>.<\/li>\n<\/ul>\nAficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial. <\/p>\nThe results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population. <\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\nFor the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\nEach patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\nAficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nAficamten became the first cardiac myosin inhibitor to show benefit in patients with nonobstructive hypertrophic cardiomyopathy.<\/li>\nIn the ACACIA-HCM trial, aficamten improved HF symptoms and peak VO2<\/sub>.<\/li>\n<\/ul>\nAficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial. <\/p>\nThe results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population. <\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\nFor the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\nEach patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\nAficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
Aficamten was associated with improvement in heart failure symptoms and exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy, according to topline results of the ACACIA-HCM trial. <\/p>\n
The results mean that aficamten (Myqorzo, Cytokinetics) is the first cardiac myosin inhibitor to show benefit in patients with nonobstructive HCM. As Healio previously reported, the ODYSSEY-HCM trial did not show a benefit for mavacamten (Camzyos, Bristol Myers Squibb) in this population. <\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\nFor the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\nEach patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\nAficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
\u201cPatients with nonobstructive HCM have no therapies approved to treat the underlying hypercontractility associated with the disease. We hope that will change with ACACIA-HCM, which is the first clinical trial to demonstrate statistically significant improvements in exercise capacity and symptom burden in patients with nonobstructive HCM,\u201d Fady I. Malik, MD, PhD<\/b>, executive vice president of research and development at Cytokinetics, said in a press release issued by Cytokinetics. \u201cWe believe that the totality and consistency of evidence favoring aficamten across multiple patient-reported and physician-assessed endpoints of symptom improvement and physical function are clinically meaningful for patients with nonobstructive HCM.\u201d<\/p>\n
For the ACACIA-HCM trial, researchers enrolled 516 participants with nonobstructive HCM and randomly assigned them to aficamten or placebo. <\/p>\n
Each patient in the aficamten group received up to four doses, starting at 5 mg, and were escalated based on echocardiographic findings at weeks 2, 4 and 6, the company stated in the release. The dose was escalated if left ventricular ejection fraction was 60% or more and deescalated if LVEF was less than 50%, according to the release.<\/p>\n
Aficamten met its dual primary endpoints, with significant improvement compared with placebo at 36 weeks in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (least square mean difference = 3; 95% CI, 0.5-5.5; P<\/i> = .021) and peak VO2<\/sub> (least square mean difference = 0.67; 95% CI, 0.22-1.1; P<\/i> = .003), according to the release.<\/p>\nThe company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
The company reported significant improvement vs. placebo in secondary endpoints including NYHA functional class, composite z<\/i> score of ventilatory efficiency and peak VO2<\/sub>, and N-terminal pro-B-type natriuretic peptide (P<\/i> for all < .001), and no new safety signals.<\/p>\n\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\nAs Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
\u201cWe look forward to presenting the results from ACACIA-HCM at an upcoming medical meeting, as well as discussing them with the U.S. FDA and other regulatory authorities,\u201d Malik said in the release.<\/p>\n
As Healio previously reported, the FDA approved aficamten in December 2025 to improve exercise capacity and HF symptoms in adults with symptomatic obstructive HCM.<\/p>\n
![\"cardiology](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/ct.svg?la=en&h=23&w=153&hash=A06CB53CC9857108FFDFA7B802CDF777\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n